These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25409188)

  • 21. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
    Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
    Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure.
    Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Nishizawa T; Noda A; Izawa H; Nagata K; Murohara T; Yokota M
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):770-9. PubMed ID: 16810078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease.
    Lavallée PC; Labreuche J; Faille D; Huisse MG; Nicaise-Roland P; Dehoux M; Gongora-Rivera F; Jaramillo A; Brenner D; Deplanque D; Klein IF; Touboul PJ; Vicaut E; Ajzenberg N;
    Cerebrovasc Dis; 2013; 36(2):131-8. PubMed ID: 24029712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation.
    Kaneyuki U; Ueda S; Yamagishi S; Kato S; Fujimura T; Shibata R; Hayashida A; Yoshimura J; Kojiro M; Oshima K; Okuda S
    Vascul Pharmacol; 2007 Apr; 46(4):286-92. PubMed ID: 17178255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of change in coronary atherosclerosis in patients with stable versus unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] study).
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Terashima M; Michishita I;
    Am J Cardiol; 2013 Apr; 111(7):923-9. PubMed ID: 23337838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
    Baldassarre D; Porta B; Camera M; Amato M; Arquati M; Brusoni B; Fiorentini C; Montorsi P; Romano S; Veglia F; Tremoli E; Cortellaro M;
    Nutr Metab Cardiovasc Dis; 2009 Sep; 19(7):481-90. PubMed ID: 19171469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
    Gotto AM; Moon J
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels.
    Hong YJ; Jeong MH; Ahn Y; Kim SW; Bae JH; Hur SH; Ahn TH; Rha SW; Kim KS; Chae IH; Kim JH; Yun KH; Oh SK;
    J Cardiol; 2012 Oct; 60(4):277-82. PubMed ID: 22658699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
    Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
    Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
    Nakagomi A; Shibui T; Kohashi K; Kosugi M; Kusama Y; Atarashi H; Shimizu W
    J Atheroscler Thromb; 2015; 22(11):1158-71. PubMed ID: 26084792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of pitavastatin versus simvastatin.
    Eriksson M; Budinski D; Hounslow N
    Adv Ther; 2011 Sep; 28(9):799-810. PubMed ID: 21874537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.
    Poolsup N; Suksomboon N; Wongyaowarat K; Rungkanchananon B; Niyomrat P; Kongsuwan S
    J Clin Pharm Ther; 2012 Apr; 37(2):166-72. PubMed ID: 21585411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
    Gocmen AY; Ocak GA; Ozbilim G; Delibas N; Gumuslu S
    Can J Physiol Pharmacol; 2013 Sep; 91(9):680-5. PubMed ID: 23984971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitavastatin - from clinical trials to clinical practice.
    Masana L
    Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of lipoprotein (a), homocysteine, and Doppler of carotid and femoral arteries in assessment of atherosclerosis in asymptomatic cardiovascular risk patients.
    El-Gendi SS; Bakeet MY; El-Hamed EA; Ibrahim FK; Ahmed R
    J Cardiol; 2008 Dec; 52(3):202-11. PubMed ID: 19027598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity.
    Wu Y; Yang L; Zhong L
    Atherosclerosis; 2010 Sep; 212(1):351-5. PubMed ID: 20594554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells.
    Kibayashi E; Urakaze M; Kobashi C; Kishida M; Takata M; Sato A; Yamazaki K; Kobayashi M
    Clin Sci (Lond); 2005 Jun; 108(6):515-21. PubMed ID: 15701058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.